UCB’s bimekizumab tops J&J’s Stelara in psoriasis study

Amgen stumps up $13.4bn to claim Otezla from Celgene

Novartis ups 2019 guidance after strong Q2

Novartis has revised its guidance for 2019 upwards after a strong set of Q2 figures, with its psoriasis drug Cosentyx being the star performer.

BMS will shed Otezla to push Celgene takeover through

Bristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion takeover of Celgene through the financial regulatory seas.

Patient Insights: Severe psoriasis & eczema

Howard Chang has lived with severe psoriasis and atopic dermatitis for almost 40 years since childhood.

AbbVie gets crucial US approval for psoriasis drug Skyrizi

With one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Skyrizi approved in the US.